Ahmed O Shalash

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9009583/ahmed-o-shalash-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14 papers	108 citations	7 h-index	10 g-index
18 ext. papers	182 ext. citations	6 avg, IF	3.2 L-index

#	Paper	IF	Citations
14	Investigation of liposomal self-adjuvanting peptide epitopes derived from conserved blood-stage Plasmodium antigens.. *PLoS ONE*, **2022**, 17, e0264961	3.7	
13	Hookworm infection: Toward development of safe and effective peptide vaccines. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 1394-1419.e6	11.5	1
12	Insights into the potential of rheological measurements in development of dry powder inhalation formulations.. *International Journal of Pharmaceutics*, **2021**, 121407	6.5	0
11	Cyclic Dipeptides: The Biological and Structural Landscape with Special Focus on the Anti-Cancer Proline-Based Scaffold. *Biomolecules*, **2021**, 11,	5.9	3
10	Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines. *Vaccines*, **2021**, 9,	5.3	13
9	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. *Advanced Science*, **2021**, 8, e2100985	13.6	8
8	Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. *Clinical and Translational Immunology*, **2021**, 10, e1260	6.8	7
7	Poly(hydrophobic amino acid)-Based Self-Adjuvanting Nanoparticles for Group A Vaccine Delivery. *Journal of Medicinal Chemistry*, **2021**, 64, 2648-2658	8.3	13
6	Oral Peptide Vaccine against Hookworm Infection: Correlation of Antibody Titers with Protective Efficacy. *Vaccines*, **2021**, 9,	5.3	4
5	Detection and Quantification of SARS-CoV-2 Receptor Binding Domain Neutralization by a Sensitive Competitive ELISA Assay.. *Vaccines*, **2021**, 9,	5.3	1
4	Modeling the performance of carrier-based dry powder inhalation formulations: Where are we, and how to get there?. *Journal of Controlled Release*, **2018**, 279, 251-261	11.7	10
3	The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance. *AAPS PharmSciTech*, **2018**, 19, 912-922	3.9	12
2	A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed. *AAPS PharmSciTech*, **2017**, 18, 2862-2870	3.9	16
1	Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content. *European Journal of Pharmaceutics and Biopharmaceutics*, **2015**, 96, 291-303	5.7	17